Hepatology

We took The Liver Meeting's 11 journey maps to educational sessions and focused on 4 that will be of interest to primary care.

Your daily dose of the clinical news you may have missed.

Among postmenopausal women taking hormones orally, the NAFLD prevalence increased from 25.3 to 29.4% while it decreased from 24 to 17.3% in those using the transdermal route.

The US Food and Drug Administration granted BTD to pegozafermin for the treatment of patients with NASH.

Resmetirom, a once-daily oral, thyroid hormone receptor (THR)-β selective agonist, targets key underlying NASH pathophysiology in the liver.

The expanded labeling for the antiviral against COVID-19 indicates no dose adjustment is required for persons across all stages of liver disease.

A daily dose of clinical news on Patient Care you may have missed.

Postmenopausal women who consumed 1 or more sugary drinks daily had a nearly 2-fold increased risk of liver cancer in a study of more than 98 000.

Factors positively associated with a timely first OAC Rx among the 41.3% who received one included male sex, certain comorbidities, other current medications, and obesity.

Your daily dose of clinical news you may have missed.

In patients with NAFLD, type 2 diabetes was found to be an independent predictor of both hepatic decompensation and incident HCC, according to meta-analysis authors. .

Your daily dose of clinical news you may have missed.

The ADA's annual update includes refined criteria for type 1 diabetes screening and detailed guidance on detection and management of NAFLD and NASH.

Pegozafermin, an investigational long-acting (FGF21) analogue, was associated with fibrosis improvement and NASH resolution in an average of 25% of study participants.

ADA 2023. Retatrutide, an investigational triple GLP-1/GIP/glucagon agonist, may provide benefits in liver fibrosis and obesity as well as in glycemic control.

In persons with biopsy-confirmed NASH, the probability of disease resolution was more than 3X greater after RGB or SG vs lifestyle intervention at 52 weeks.

Your daily dose of clinical news you may have missed.

A population-based study found metabolic dysfunction more prevalent than ultrasonographic steatosis in patients recovered from HCV and a better predictive tool for disease progression.

Risk of T2D was reduced by 49% over a 10-year follow up period among study participants who followed a vigorous or moderate exercise plan vs those who did not engage in exercise.

Your daily dose of clinical news you may have missed.

Adults with T2D may be able to reduce their liver fat and improve their liver fibrosis stage with reductions in HbA1c, according to findings from a retrospective analysis.

Patient Care Guideline Toplines summarize newly revised and updated clinical recommendations from professional societies for convenient, at-a-glance review.

Find a compact sampling of 2022 cardiovascular disease research reviewed on Patient Care, chosen by the editorial staff.

Bariatric surgery reduced by half the risk of CV events including myocardial infarction, heart failure, and stroke compared to nonsurgical care.

Studies of cardiometabolic disease pathophysiology, prevention, and treatment make science news every day. Find 12 here, at-a-glance.